In a phase III randomized controlled trial, belimumab, a fully human mAb against BAFF, has been shown to have a modest effect in patients with active SLE.11 This has led to the regulatory approval of belimumab for the treatment of SLE by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.